8-thia-tricyclo[7.3.1,0^2,7]trideca-2(7),3,5-triene | 6675-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫铬烷
• 英文名称: 8-thia-tricyclo[7.3.1,0^2,7]trideca-2(7),3,5-triene
• 英文别名: 3,4,5,6-Tetrahydro-2H-2,6-methano-benzo[b]thiocin；8-Thiatricyclo[7.3.1.02,7]trideca-2,4,6-triene；8-thiatricyclo[7.3.1.02,7]trideca-2,4,6-triene
• CAS: 6675-32-7
• 化学式: C₁₂H₁₄S
• 分子量: 190.309
• InChiKey: LJGCTJAPBHHCTA-UHFFFAOYSA-N

物化性质

• 沸点：
  100 °C(Press: 0.2 Torr)
• 密度：
  1.119±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  8-thia-tricyclo[7.3.1,0^2,7]trideca-2(7),3,5-triene 在 双氧水 、 溶剂黄146 作用下， 生成 1,1-Dioxo-3,4,5,6-tetrahydro-2H-1λ6-2,6-methano-benzo[b]thiocin
  参考文献：
  名称：

  Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer

  摘要：

  A phase II study was conducted to assess the activity and toxicity of irinotecan (CPT-11) and carboplatin (CBDCA) combination chemotherapy for advanced non-small-cell lung cancer (NSCLC). Eligibility included chemo-naive advanced NSCLC patients with measurable disease and a good performance status. CPT-11 of 50 mg/m(2) was administered as a 90-min intravenous infusion on days 1, 8, and 15. CBDCA dosed to an area under the concentration-time curve of 5 mg min/ml, using Calvert's formula, was administered by 90-min infusion after the CPT-11 infusion on day 1. Treatment was repeated 28 days interval for at least two cycles. Haematopoietic growth factors were not routinely used. From December 1997 to January 1999, 36 patients were entered into the study. The overall response rate was 25.0% (95% confidence interval: 12.1-42.2%). The median survival time and the 1-year survival rate were 10.2 months and 42.2%, respectively. Major toxicity by Japan Clinical Oncology Group criteria was as follows: grade 3-4 neutropenia 76.5%; grade 3 anemia 26.5%; grade 3/4 thrombocytopenia 47.1%; grade 3 nausea/vomiting 36.1%; grade 3-4 diarrhoea 5.9%; grade 3 alopecia 5.9%; grade 3-4 skin rush 2.9%. Four patients developed febrile neutropenia and only one had serious diarrhea induced by CPT-11. Actual relative delivery dose of CPT-11 to the projected one on days 8 and 15 were 0.86 and 0.43, respectively. It seemed that CPT-11 and CBDCA was more toxic regimen than CPT-11 and CDDP in advanced NSCLC. The relatively disappointing response rate could be related with low dose intensity of CPT-11. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

  DOI：

  10.1016/s0169-5002(02)00304-5
• 作为产物：
  描述：

  二苯并噻吩 在 乙醇 、 氨 、 sodium 作用下， 生成 8-thia-tricyclo[7.3.1,0^2,7]trideca-2(7),3,5-triene
  参考文献：
  名称：

  Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer

  摘要：

  A phase II study was conducted to assess the activity and toxicity of irinotecan (CPT-11) and carboplatin (CBDCA) combination chemotherapy for advanced non-small-cell lung cancer (NSCLC). Eligibility included chemo-naive advanced NSCLC patients with measurable disease and a good performance status. CPT-11 of 50 mg/m(2) was administered as a 90-min intravenous infusion on days 1, 8, and 15. CBDCA dosed to an area under the concentration-time curve of 5 mg min/ml, using Calvert's formula, was administered by 90-min infusion after the CPT-11 infusion on day 1. Treatment was repeated 28 days interval for at least two cycles. Haematopoietic growth factors were not routinely used. From December 1997 to January 1999, 36 patients were entered into the study. The overall response rate was 25.0% (95% confidence interval: 12.1-42.2%). The median survival time and the 1-year survival rate were 10.2 months and 42.2%, respectively. Major toxicity by Japan Clinical Oncology Group criteria was as follows: grade 3-4 neutropenia 76.5%; grade 3 anemia 26.5%; grade 3/4 thrombocytopenia 47.1%; grade 3 nausea/vomiting 36.1%; grade 3-4 diarrhoea 5.9%; grade 3 alopecia 5.9%; grade 3-4 skin rush 2.9%. Four patients developed febrile neutropenia and only one had serious diarrhea induced by CPT-11. Actual relative delivery dose of CPT-11 to the projected one on days 8 and 15 were 0.86 and 0.43, respectively. It seemed that CPT-11 and CBDCA was more toxic regimen than CPT-11 and CDDP in advanced NSCLC. The relatively disappointing response rate could be related with low dose intensity of CPT-11. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

  DOI：

  10.1016/s0169-5002(02)00304-5

文献信息

• Molecular rearrangement in the Birch reduction of dibenzothiophenes
  作者：Pavel Kukula、Andreas Dutly、Heinz Rüegger、Roel Prins

  DOI：10.1016/j.tetlet.2007.06.026

  日期：2007.8

  A molecular rearrangement observed during the Birch reduction of dibenzothiophene and 4,6-dimethyl-dibenzothiophene was explored and a mechanism for the rearrangement has been proposed. (c) 2007 Elsevier Ltd. All rights reserved.
• Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer
  作者：Koji Takeda、Nobuhide Takifuji、Hisao Uejima、Naruo Yoshimura、Kazuhiko Terakawa、Shunichi Negoro

  DOI：10.1016/s0169-5002(02)00304-5

  日期：2002.12

  A phase II study was conducted to assess the activity and toxicity of irinotecan (CPT-11) and carboplatin (CBDCA) combination chemotherapy for advanced non-small-cell lung cancer (NSCLC). Eligibility included chemo-naive advanced NSCLC patients with measurable disease and a good performance status. CPT-11 of 50 mg/m(2) was administered as a 90-min intravenous infusion on days 1, 8, and 15. CBDCA dosed to an area under the concentration-time curve of 5 mg min/ml, using Calvert's formula, was administered by 90-min infusion after the CPT-11 infusion on day 1. Treatment was repeated 28 days interval for at least two cycles. Haematopoietic growth factors were not routinely used. From December 1997 to January 1999, 36 patients were entered into the study. The overall response rate was 25.0% (95% confidence interval: 12.1-42.2%). The median survival time and the 1-year survival rate were 10.2 months and 42.2%, respectively. Major toxicity by Japan Clinical Oncology Group criteria was as follows: grade 3-4 neutropenia 76.5%; grade 3 anemia 26.5%; grade 3/4 thrombocytopenia 47.1%; grade 3 nausea/vomiting 36.1%; grade 3-4 diarrhoea 5.9%; grade 3 alopecia 5.9%; grade 3-4 skin rush 2.9%. Four patients developed febrile neutropenia and only one had serious diarrhea induced by CPT-11. Actual relative delivery dose of CPT-11 to the projected one on days 8 and 15 were 0.86 and 0.43, respectively. It seemed that CPT-11 and CBDCA was more toxic regimen than CPT-11 and CDDP in advanced NSCLC. The relatively disappointing response rate could be related with low dose intensity of CPT-11. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.